6.3 Acquired Pediatric Heart Disease: Kawasaki Disease, Rheumatic Fever & Heart Failure

Acquired Pediatric Heart Disease: Kawasaki Disease, Rheumatic Fever & Heart Failure

Quick Clinical Summary: Acquired pediatric heart disease encompasses cardiovascular disorders that develop after birth as a consequence of systemic inflammation, infection, autoimmune response, or secondary myocardial decompensation. Kawasaki Disease is an acute medium-vessel systemic vasculitis with a grave predilection for coronary artery aneurysm formation, requiring emergent single-dose intravenous immunoglobulin (IVIG) and high-dose aspirin within 10 days of fever onset. Acute Rheumatic Fever (ARF) is a delayed autoimmune carditis and polyarthritis triggered by untreated Group A beta-hemolytic streptococcal pharyngitis, necessitating secondary antibiotic prophylaxis to avert permanent rheumatic valvular disease. Pediatric Congestive Heart Failure pharmacotherapy relies on precise administration of inotropic agents (digoxin), loop diuretics (furosemide), and afterload-reducing ACE inhibitors under strict laboratory and hemodynamic safety thresholds.

---

1. Kawasaki Disease (Mucocutaneous Lymph Node Syndrome)

Kawasaki Disease (KD) is an acute, self-limiting systemic vasculitis of unknown etiology that primarily affects medium-sized muscular arteries. It is the leading cause of acquired heart disease in children in the United States and developed nations, surpassing acute rheumatic fever. Approximately 80% to 85% of cases occur in children under 5 years of age, with a peak incidence occurring between 18 and 24 months of age. Children of Asian and Pacific Islander descent exhibit the highest geographic and racial susceptibility.

Vascular Pathology & Coronary Artery Complications

The inflammatory cascade in Kawasaki disease targets the vascular endothelium of medium-sized arteries, most notably the coronary arteries. Infiltration of neutrophils, T-lymphocytes, and myofibroblasts produces extensive fragmentation of the internal elastic lamina and destruction of the muscular media. The weakened arterial wall balloons outward under systemic arterial pressure, resulting in:

• Coronary Ectasia: Diffuse, mild luminal dilation that typically resolves over several months.
• Coronary Artery Aneurysms: Occur in 20% to 25% of untreated children, typically forming 2 to 4 weeks after fever onset.
• Giant Aneurysms: Defined as an internal lumen diameter >8 mm (or Z-score >= 10). Giant aneurysms carry a devastating prognosis: they rarely regress and are prone to sluggish flow, intraluminal thrombosis, sudden myocardial infarction, rupture, and sudden cardiac death.

Clinical Phases of Kawasaki Disease

• Acute Febrile Phase (Days 1–11): Sudden onset of high, remittent fever (>39°C to 40°C) unresponsive to antibiotics and standard antipyretics; emergence of conjunctival injection, strawberry tongue, polymorphous rash, indurated extremity edema, and severe irritability. Subclinical myocarditis is universal.
• Subacute Phase (Days 11–25): Defervescence; clinical signs resolve except for dry, cracked lips, anorexia, and characteristic periungual desquamation. Profound thrombocytosis emerges, with platelet counts frequently exceeding 1,000,000/mcL. This phase represents the peak window for coronary artery aneurysm formation and sudden thrombotic myocardial infarction.
• Convalescent Phase (Days 25–60+): All clinical manifestations have resolved, but inflammatory markers (ESR, CRP) remain elevated until full vascular healing occurs. Transverse grooves across the fingernails (Beau lines) frequently appear.

American Heart Association Diagnostic Criteria

Because no single laboratory test is diagnostic, Kawasaki disease is a clinical diagnosis. The patient must present with persistent fever lasting at least 5 days (or >= 4 days in experienced hands when classic criteria are present) PLUS at least 4 of the following 5 classic clinical features:

Evidence-Based Treatment Protocol

The overarching goal of therapy is the rapid suppression of systemic vascular inflammation to prevent coronary artery aneurysms:

1. Intravenous Immunoglobulin (IVIG):
   • Dose: Single high-dose infusion of 2 g/kg IV administered over 10 to 12 hours.
   • Timing: Must be initiated within the first 10 days of illness (ideally within 7 days). Treatment within 10 days reduces the incidence of coronary artery aneurysms from 25% down to <4% to 5%.
   • IVIG Resistance: If fever persists or recurs >= 36 hours after completion of the initial IVIG infusion (occurs in 10–15% of patients), a second dose of 2 g/kg IVIG or intravenous methylprednisolone / infliximab is administered.
2. Aspirin (Acetylsalicylic Acid - ASA):
   • Acute Anti-inflammatory Phase: High-dose aspirin (80 to 100 mg/kg/day orally divided every 6 hours) given concurrently with IVIG until the child has been afebrile for 48 to 72 hours (or through day 14 of illness).
   • Maintenance Antiplatelet Phase: Once afebrile, aspirin is reduced to low-dose antiplatelet therapy (3 to 5 mg/kg/day orally as a single daily dose). Maintained for 6 to 8 weeks until repeat echocardiography confirms normal coronary arteries and ESR/platelet counts normalize.
   • If coronary aneurysms are detected, low-dose aspirin (plus systemic anticoagulation with warfarin or low-molecular-weight heparin for giant aneurysms) is continued indefinitely.

1. Postponement of Live-Attenuated Vaccines:
   • High-dose IVIG supplies an enormous concentration of passively acquired neutralizing antibodies against measles, mumps, rubella, and varicella, which inhibits the child's ability to mount an active protective immune response.
   • Clinical Mandate: Live viral vaccines (MMR and Varicella) must be deferred for 11 months following high-dose IVIG administration. If a child received MMR or varicella within the 2 weeks preceding IVIG, the child must be revaccinated 11 months later.

---

2. Acute Rheumatic Fever (ARF) & Rheumatic Heart Disease

Acute Rheumatic Fever (ARF) is a delayed autoimmune, multi-system inflammatory sequela that develops 2 to 4 weeks after an untreated or undertreated pharyngeal infection caused by Group A beta-hemolytic Streptococcus (GAS / Streptococcus pyogenes).

• Etiologic Boundary: ARF occurs exclusively following streptococcal pharyngitis; streptococcal skin infections (impetigo / pyoderma) do not cause rheumatic fever (though they can cause post-streptococcal glomerulonephritis).

Pathogenesis: Molecular Mimicry

The disease does not result from direct bacterial invasion of cardiac tissue, but rather from an abnormal humoral and cell-mediated autoimmune response driven by molecular mimicry. Streptococcal cell wall M-proteins and N-acetylglucosamine share dense structural homology with human cardiac proteins (cardiac myosin, actin, laminin), synovial joint endothelium, and basal ganglia neuronal proteins. Antibodies and CD4+ T-cells raised against Streptococcus cross-react with host tissues, triggering intense inflammation:

• Aschoff Bodies: Characteristic granulomatous inflammatory nodules containing multinucleated giant cells (Aschoff cells) and swollen collagen fibrils, found within the myocardium in rheumatic carditis.

Diagnosis: The Modified Jones Criteria

To establish a diagnosis of Acute Rheumatic Fever, there must be verified evidence of a preceding GAS infection PLUS either two Major criteria OR one Major and two Minor criteria.

Diagnostic Requirement: Preceding GAS Evidence + (2 Major  OR  1 Major + 2 Minor)
Evidence of Preceding GAS:
- Positive throat culture for GAS, OR
- Positive rapid streptococcal antigen detection test (RADT), OR
- Elevated or rising Antistreptolysin O (ASO) titer or Anti-DNase B titer

The Major Diagnostic Manifestations (JONES Mnemonic)

1. J - Joints (Migratory Polyarthritis): Present in 75% of cases. An exquisitely painful, inflammatory arthritis affecting the large joints (knees, ankles, elbows, wrists). The arthritis is characteristically migratory: inflammation flares in one joint for several days, subsides completely without residual joint deformity, and moves to another joint. It displays a dramatic, rapid response to aspirin or NSAID therapy.
2. O - Carditis (Pancarditis): Present in 50% to 60% of cases. Inflames endocardium, myocardium, and pericardium. Endocarditis (valvulitis) is the clinical hallmark, universally attacking the Mitral Valve (causing mitral regurgitation, auscultated as an apical, high-pitched holosystolic murmur radiating to the left axilla) and secondarily the Aortic Valve (aortic regurgitation: early diastolic decrescendo murmur at the LUSB). Carditis is the only manifestation of ARF that leads to permanent, chronic disability or death (Rheumatic Heart Disease).
3. N - Nodules (Subcutaneous Nodules): Present in <10% of cases. Small (0.5 to 2 cm), firm, non-tender, painless nodules located over bony prominences and extensor tendon surfaces (elbows, wrists, knees, occiput, vertebrae). Strongly correlated with severe, active carditis.
4. E - Erythema Marginatum: Present in <5% of cases. A distinct, non-pruritic, pink-red macular rash characterized by sharp, elevated, serpiginous erythematous borders with central clearing ("ring-like" or serpentine margins). Located primarily on the trunk and proximal extremities; it strictly spares the face. The rash is evanescent and accentuated by heat (e.g., a warm bath).
5. S - Sydenham Chorea ("St. Vitus' Dance"): Present in 10% to 15% of cases. A delayed central nervous system manifestation resulting from autoimmune basal ganglia vasculitis. Characterized by sudden, aimless, rapid, involuntary choreiform movements of the face, hands, and feet, accompanied by muscle weakness, slurred speech, and profound emotional lability. Often presents 2 to 6 months after the initial infection, frequently as the sole manifestation of ARF.

Minor Diagnostic Criteria

• Clinical Findings: Arthralgia (joint pain without objective inflammation; cannot be counted if polyarthritis is used as a major criterion); Fever (temperature >= 38.5°C in moderate/low-risk populations).
• Laboratory Findings: Elevated acute-phase reactants (ESR >= 60 mm/hr and/or CRP >= 3.0 mg/dL).
• Electrocardiographic Findings: Prolonged PR interval on ECG (first-degree AV block adjusted for age; cannot be counted if carditis is used as a major criterion).

Clinical Management & Secondary Antibiotic Prophylaxis

• Eradication of Streptococcus: Immediate administration of intramuscular Benzathine Penicillin G (single dose: 600,000 units for children <= 27 kg; 1,200,000 units for children >27 kg) or oral Penicillin V (250–500 mg 2–3 times daily for 10 days). Oral erythromycin or azithromycin is utilized for penicillin-allergic patients.
• Anti-inflammatory Therapy: High-dose aspirin (50 to 100 mg/kg/day divided every 6 hours) for arthritis and mild carditis; Oral Prednisone (1 to 2 mg/kg/day for 2 to 4 weeks) is indicated for severe carditis with cardiomegaly, pericarditis, or congestive heart failure. Strict bed rest is enforced during the active inflammatory phase.

Continuous Secondary Antibiotic Prophylaxis Guidelines

A patient who has experienced an episode of ARF is at exceptionally high risk for recurrent streptococcal infections triggering recurrent attacks, which cause cumulative, progressive fibrotic destruction of the mitral and aortic valves (Rheumatic Heart Disease). Continuous secondary prophylaxis is mandatory:

• Preferred Regimen: Intramuscular Benzathine Penicillin G every 4 weeks (every 3 weeks in high-risk environments or patients with severe carditis).
• Alternative Regimens: Oral Penicillin V potassium (250 mg twice daily) or oral Sulfadiazine (0.5 to 1.0 g once daily).

---

3. Pediatric Heart Failure Pharmacotherapy: Digoxin, Diuretics & ACE Inhibitors

Pharmacological management of pediatric congestive heart failure aims to enhance myocardial contractility, eliminate excessive fluid volume, and reduce ventricular afterload.

Digoxin (Lanoxin) Inotropic Therapy

Digoxin is a cardiac glycoside that reversibly inhibits the myocardial cell membrane Na+/K+ ATPase enzyme. This increases intracellular sodium, which in turn slows the sodium-calcium exchanger, increasing intracellular calcium availability within cardiac myocytes. This produces:

• Positive Inotrope: Enhances myocardial contractility and increases cardiac output.
• Negative Chronotrope: Stimulates the vagus nerve and slows atrioventricular (AV) node conduction velocity, decreasing resting heart rate.
• Narrow Therapeutic Window: Serum therapeutic level is 0.8 to 2.0 ng/mL. Serum concentrations >2.0 ng/mL are considered toxic.

Critical Nursing Administration Protocols for Digoxin

1. Auscultate Apical Pulse for 1 Full Minute: Never rely on a radial pulse, automated monitor, or 30-second count. Auscultate with a pediatric stethoscope at the apex (4th intercostal space lateral to midclavicular line in infants).
2. Strict Heart Rate Withhold Parameters:
   • Infants and Young Toddlers: Withhold dose and notify provider if apical heart rate is <90 to 110 beats/min (per institutional guidelines; generally <90 bpm in older infants, <100–110 bpm in neonates).
   • Older Children (Preschool to School-Age): Withhold dose and notify provider if apical heart rate is <70 beats/min.
   • Adolescents: Withhold dose and notify provider if apical heart rate is <60 beats/min.
3. Independent Double-Check: Digoxin is a high-alert pediatric medication. Infant doses are minute, rarely exceeding 1 mL (50 mcg). Any calculated volume greater than 1 mL must be regarded with extreme suspicion and immediately verified with the prescriber and a second registered nurse.
4. Handling Missed or Vomited Doses:
   • If the infant spits up or vomits after administration, DO NOT RE-ADMINISTER THE DOSE. It is impossible to ascertain how much drug was absorbed, and re-dosing risks precipitating lethal toxicity.
   • If a dose is missed and noticed within 4 hours, administer the dose; if >4 hours have elapsed, withhold that dose and resume at the next scheduled time. Never administer a double dose.

Manifestations of Digoxin Toxicity

• Cardiac Manifestations: Sinus bradycardia is the earliest, most reliable cardiac indicator of toxicity in infants. Other signs include prolonged PR interval, AV block, ventricular bigeminy, and premature ventricular contractions (PVCs).
• Gastrointestinal Manifestations: Anorexia, poor feeding, nausea, and repeated vomiting (the earliest systemic warning sign of toxicity in infants).
• Neurological & Visual Signs: Lethargy, drowsiness, generalized muscular weakness, blurred vision, and yellow-green halos or chromatopsia around light sources (reported by older children).

• Antidote: Digoxin-specific antibody antigen-binding fragments (DigiFab / Digibind) administered IV for life-threatening arrhythmias, severe refractory hyperkalemia, or massive acute ingestion.

Loop Diuretic Therapy: Furosemide (Lasix)

• Mechanism: Inhibits the Na+-K+-2Cl- cotransporter in the thick ascending limb of the loop of Henle, promoting massive excretion of sodium, chloride, potassium, and free water to decrease venous preload and resolve pulmonary congestion.
• Adverse Effects: Hypokalemia, hypochloremic metabolic alkalosis, hypovolemia/dehydration, and ototoxicity (especially when administered as rapid IV push or combined with aminoglycosides).
• Nursing Assessments: Monitor serum electrolytes closely; administer oral potassium chloride supplements or co-administer potassium-sparing diuretics (spironolactone) as ordered. Track strict daily naked morning weights and diaper weights (1 g = 1 mL; normal infant output: 1–2 mL/kg/hr).

Afterload Reduction: ACE Inhibitors (Captopril, Enalapril)

• Mechanism: Blocks the conversion of angiotensin I to angiotensin II, a potent systemic vasoconstrictor. Promotes systemic arterial vasodilation, sharply reduces Systemic Vascular Resistance (afterload), facilitates forward left ventricular emptying, and diminishes aldosterone-mediated sodium retention.
• Nursing Priorities:
  • Assess blood pressure immediately before administration and 30 to 60 minutes post-dose; monitor for severe first-dose hypotension.
  • Monitor renal function parameters (BUN, serum creatinine).
  • Monitor serum potassium: ACE inhibitors decrease aldosterone secretion, promoting potassium retention and predisposing patients to hyperkalemia (especially if co-prescribed with spironolactone or potassium supplements).
  • Monitor for dry persistent cough or life-threatening angioedema.

---

4. Pediatric Heart Failure Pharmacology Reference Matrix